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Accepted 12 March 2019Background: The peroxisomeproliferator-activated receptorγ (PPARγ) is a ligand-dependent transcription factor
involved in many aspects of metabolism, immune response and development. Numerous studies relying on
tissue-speciﬁc invalidation of the Pparg gene have shown distinct facets of its activity, whereas the effects of its
systemic inactivation remain unexplored due to embryonic lethality. By maintaining PPARγ expression in the
placenta, we recently generated a mouse model carrying Pparg full body deletion (PpargΔ/Δ), which in contrast
to a previously published model is totally deprived of any form of adipose tissue. Herein, we propose an in-
depth study of the metabolic alterations observed in this new model.
Methods: Young adult mice, both males and females analyzed separately, were ﬁrst phenotyped for their gross
anatomical alterations. Systemicmetabolic parameters were analyzed in the blood, in static and in dynamic con-
ditions. A full exploration of energy metabolism was performed in calorimetric cages as well as in metabolic
cages. Our study was completed by expression analyses of a set of speciﬁc genes.
Main ﬁndings: PpargΔ/Δmice show a striking complete absence of any form of adipose tissue, which triggers a com-
plexmetabolic phenotype including increased leanmasswith organomegaly, hypermetabolism, urinary energy loss,
hyperphagia, and increased amino acidmetabolism. PpargΔ/Δmice develop severe type 2 diabetes, characterized by
hyperglycemia, hyperinsulinemia, polyuria and polydispsia. They show a remarkablemetabolic inﬂexibility, as indi-
cated by the inability to shift substrate oxidation between glucose and lipids, in both ad libitum fed state and fed/
fasted/refed transitions. Moreover, upon fasting PpargΔ/Δmice enter a severe hypometabolic state.
Conclusions: Our data comprehensively describe the impact of lipoatrophy on metabolic homeostasis. As such, the
presented data on PpargΔ/Δmice gives new clues on what and how to explore severe lipodystrophy and its subse-
quent metabolic complications in human.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article undermass are associatedwith severe pathological states. Obesity is a risk fac-
tor for metabolic syndrome associated with hyperglycemia, hyperten-
sion, hyperlipidemia, insulin resistance, and with increased risk for
cardiovascular diseases and type-2 diabetes [1,2]. It is accompanied by
pronounced alterations in the secretory proﬁle of adipocytes and mac-
rophages, resulting in chronic low-grade inﬂammation and subsequent
adipocyte dysfunction [3–5]. Opposite to obesity, the lack of fat is called
lipoatrophy. The most severe human form is the Berardinelli-Seip syn-
drome, which is a congenital generalized lipodystrophy provoked by
mutations in BSCL2 or in AGPAT2 genes. Interestingly, lipodystrophic pa-
tients suffer from the same disorders as obese patients, including severe
insulin resistance and type-2 diabetes [6,7]. A unifying model proposes
that when adipose tissue expandability is exhausted, such as in the
presence of excess of lipids (obesity) or of insufﬁcient body fat capacity
(lipodistrophy), lipids cannot be safely stored in ectopic fat and accu-
mulate in ectopic tissues, promoting lipotoxicity, insulin resistance
and apoptosis [8–10].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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master regulator peroxisomeproliferator-activated receptorγ (PPARγ),
a ligand-dependent transcription factor belonging to the nuclear recep-
tor superfamily [11,12]. PPARγ has many other metabolic activities in-
cluding insulin sensitization. Indeed, synthetic PPARγ ligands such as
thiazolidinediones (TZDs) have proven to be potent in the treatment
of type-2 diabetes [13,14]. Conversely, rare natural heterozygous muta-
tions in humans affecting PPARγ binding or activity lead to the develop-
ment of partial lipodystrophy, insulinoresistance, hepatic steatosis and
hypertriglyceridemia [7,15]. Moreover, deletion of the PPARγ2 isoform
in the obese ob/ob background [16] as well as the fat-speciﬁc PPARγ de-
letion inAdipoq-Cre/Ppargﬂ/ﬂmice (PPARγFKOmice) [17], invariably led
to insulin resistance, hyperglycemia and hyperlipidemia, although
resulting in different degrees of adipose tissue reduction. Likewise, the
deletion of PPARγ in muscle conﬁrmed its essential role to maintain
whole body insulin sensitivity [18]. Finally, macrophage-speciﬁc dele-
tion of PPARγ predisposed mice to diet-induced insulin resistance [19].
The effect of PPARγ whole body deletion could however not be ex-
plored due to placental defects [20,21]. In a ﬁrst attempt to circumvent
this embryonic lethality by preserving PPARγ expression in the pla-
centa, Meox-Cre mice were bred with PPARγ-ﬂoxed mice [22]. How-
ever, this approach gave rise to high mosaicism with various degree of
Cre-dependent recombination depending on tissues (our unpublished
results and [23]).
By using Sox2-Cre mediated recombination instead to delete PPARγ
in the embryo while maintaining its expression in the placenta [23], we
obtained viable whole-body PPARγ null pups [21].Whereas PPARγ null
mice show post-natal lethality and delayed growth during the suckling
period, they recover and grow properly after weaning. Importantly,
throughout their life, PPARγ null mice exhibit a total lack of white and
brown adipose tissue. In the present report, we analyzed the severe
metabolic disorders that accompany this total lipoatrophy.
2. Materials and methods
2.1. Animals
Animal care and treatments were performed in agreement with the
guidelines established by the European Community Council Directives
(86/609/EEC) and were approved by the commission for animal experi-
mentation of the cantonal veterinary services (Canton of Vaud). Whole
body Pparg null mice were obtained as previously described [24]. Mice
were kept in a 12:12 h light:dark cycle and fed a standard chow diet (cat.
3436, Kliba Nafag, Kaiseraugst, Switzerland) with water ad libitum. For
growth curves PpargΔ/Δ and littermate control males and females (N =
5–10) were distributed among cages as random blocks of 1 Pparg null
and 2 control mice. Random blocking was also used in all experiments.
2.2. Mouse embryonic ﬁbroblasts
MEFswere isolated fromE13.5 embryos. Brieﬂy, after removal of head
and internal organs, embryoswereminced and incubated for 20min at 37
°C in 0.25% Trypsin-EDTA. Cell suspensions were centrifuged, suspended
with cell culture media (DMEM/F-12 supplemented with 10% FBS,
20 mM glutamine, and penicillin/streptomycin), plated in P100, and cul-
tured at 37 °C and 5% CO2. Cells were differentiated in vitro as previously
reported [25], with orwithout rosiglitazone (0.5 μM). DifferentiatedMEFs
were ﬁxed in 4% paraformaldehyde and stained with 0.3% Oil-Red-O
(Sigma) for 10 min.
2.3. Clinical parameters
Resistin and leptin were measured using the Luminex technology
(Bioplex, Bio-Rad). Plasma and urine biochemical parameters were
evaluated on a Cobas C111 analyzer (Roche Diagnostics, Rotkreuz,
Switzerland) at the Mouse Metabolic Evaluation Facility of theUniversity of Lausanne. Insulin levelsweremeasuredwith theMercodia
Ultrasensitive insulin ELISA (Mercodia AB, Sweden).
2.4. Body composition
Analyses were performed in duplicate for each mouse with the
EchoMRI™ qNMR system (Echo Medical Systems, Houston, TX, USA)
under isoﬂurane anesthesia at the Mouse Metabolic Evaluation Facility
(MEF) of the University of Lausanne.
2.5. Body temperature
The temperature was measured in 12 weeks old females (N = 6)
using a rectal probe (Bioseb) after 4 days of acclimation.
2.6. Glucose metabolism
GTTwas performed in 10–12weeks oldmale and female control and
PpargΔ/Δ mice (N = 8). After 16 h of fasting, glucose (2 g/kg) was
injected intraperitoneally. Blood was collected from the tail vein at 0,
15, 30, 60 and 120 min after the injection and glycemia was evaluated
by the use of a glucometer (Bayer Breeze 2, Canada). For the ITT,
12 weeks old male and female mice (N= 3–6 per group) were fasted
6 h and then injected intraperitoneally with insulin (0.6 U/Kg). Blood
glucose was measured at 0, 15, 30 and 60 min after insulin injection.
2.7. Indirect calorimetry
Indirect calorimetry was performed in 12 weeks old mice placed in
individual chambers in a 12 cages CLAMS system (Columbus Instru-
ments, OH, USA), placed in a temperature-controlled chamber. For ad
libitum measurements, CO2 production, locomotor activity, food and
water intake were recorded during 2 cycles of 24-h, with unrestricted
food access (N=6). For the response to feeding-fasting-refeeding tran-
sitions, indirect calorimetry measurements included a full day in the ad
libitum condition, followed by an overnight (16 h) fasting and a diurnal
refeeding period (N= 3; results replicated in 6 independent cohorts of
both males and females). For thermoneutrality experiments, calorime-
try measurements were recorded during three consecutive intervals of
24 h: a ﬁrst cohort (N = 3) was put at ambient temperature at 23 °C,
then 32 °C, then 33 °C; a second independent cohort (N = 3) was put
at ambient temperature at 23 °C, then 32 °C, then 30 °C. Fermentation
artifacts were prevented by trapping urine into diaper strips placed un-
derneath the chamberﬂoors.Moreover, during thermoneutrality exper-
iments, mice were transferred every 24 h at the time of temperature
transitions into new experimental cages conditioned with their own
smell.
2.8. Urine/feces analyses
Mice were acclimated to metabolic cages (Tecniplast 3600 M021).
Then urine and feces were collected over three consecutive intervals:
1) 24 h with food ad libitum, 2) ﬁrst 5 h of fasting, and 3) successive
9 h of fasting (N = 7). The energy content of food and feces was mea-
sured with a calorimetric bomb (IKA C200, Staufen, Germany). Metabo-
lizable energywas estimated by subtracting the 24 h hour energy loss in
both urine (approximated as the energy lost as glucose, TGs, NEFAs, ke-
tone bodies, proteins and urea), and in feces, to the 24 h feeding gross
energy (16.1MJ/kg of chow diet).
2.9. Histology and morphometry
After dissection organswere ﬁxed 4 h in 4%PFA– PBS solution at 4 °C
and were parafﬁn embedded. Parafﬁn sections of 4 μm thickness were
made and stained with Hematoxylin-Eosin. For cryosections, organs
were embedded in OCT (Sakura, Torrance, CA) and frozen on dry-ice.
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with anti-insulin antibody (dil 1:400, AO564, Dako). β-cell mass was
calculated by measuring β-cell surface area using ImageJ software in
5–8 sections per pancreas and 4–5 pancreas per group. β-cell mass
was extrapolated based on individual pancreas weight.
2.10. Protein expression
Proteins were extracted from frozen gastrocnemius using M-PER
lysing buffer (78501) with added protease and phosphatase inhibitors
(78426, 78429 Thermoﬁsher). Western blot was performed with stan-
dard procedures, with the following antibodies (Akt (9272) and
Phospho-Akt (9271 Cell Signaling)). Chemiluminescence was detected
with SuperSignal West Pico (Pierce). Blots were exposed digitally
using the Fusion FX system (Vilber) and bands were quantiﬁed using
ImageJ.
2.11. Real-time quantitative PCR
Total RNA was isolated after homogenisation in TRI-Reagent
(Ambion, Thermo Fisher Scientiﬁc Inc.) and extraction with RNeasy
Mini Kit (Qiagen). Gene expressionwas analyzed by real-time quantita-
tive PCR (FastStart Universal SYBR Green Master, Roche, USA) in a
Stratagene MX3005P Detection System (Agilent Technologies, USA).
Ribosomal protein S9 (Rps9)was used as housekeeping gene. Primer se-
quences are available upon request.
2.12. Statistical analyses
Values, expressed as mean ± SEM, were analyzed using Prism 5.0
(GraphPad Software, USA). Student's t-test, one-way or two-way
ANOVA with Bonferroni post-test for multiple group comparisons
were used to assess statistical signiﬁcance. For leptin, resistin and insu-
lin levels, data were log-transformed to show normal distribution for
statistical analysis. A P value b0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Generalized lipodystrophy and organomegalia in PpargΔ/Δmice
PPARγwhole body deletion was obtained in Sox2-Cretg/+;PpargΔ/emΔ
(called hereafter PpargΔ/Δ) mice, as previously described [24] and
PPARγ expression was undetectable in spleen, liver, muscle, heart,
colon, and brain (data not shown). Consistent with the fundamental
role of PPARγ in adipogenesis [11,26], embryonic ﬁbroblasts isolated
from PpargΔ/Δ embryos could not differentiate in adipocytes (Suppl.
Fig. 1). Accordingly, PpargΔ/Δmice presented a generalized lipoatrophy,
characterized by the complete absence of interscapular brown (BAT)
and white (WAT) adipose tissues (Fig. 1A), as well as perirenal (Fig. 1B),
mesenteric, perigonadal and subcutaneous WAT (Fig. 1C). Circulating
adipokines such as resistin and adiponectin were not detectable, while
leptin was extremely low in both male and female PpargΔ/Δ mice
(Fig. 1D and data not shown). While similar at birth, PpargΔ/Δ mice
showed post-natal growth retardation during the suckling period
(Fig. 1E), during which around 30% of pups died. After weaning
(3 weeks), the surviving pups started to grow faster, reaching the same
body weight as control mice at 6–7 weeks and becoming heavier than
their control littermates between 8 and 12 weeks of age (Fig. 1E), with
no more lethality. Strikingly, the higher body weight in PpargΔ/Δ mice
was almost exclusively due to a very signiﬁcant increase in lean mass,
while fat content was barely augmented with body weight, in contrast
to what was observed in littermate control mice (Fig. 1F, G) Indeed,
adult PpargΔ/Δ mice showed organomegaly affecting particularly the
liver (Fig. 1C, H) but also intestine and spleen (Suppl. Fig. 2 and [27]),whereas heart andmuscle masses were unchanged and reduced, respec-
tively (Suppl. Fig. 2 and [28]). In absence of adipose tissue, PpargΔ/Δmice
showed ectopic lipid deposition in the liver (Fig. 1I), but not in muscle
[28].
3.2. Deep alterations of glucose homeostasis in PpargΔ/Δ mice
At 10–12weeksmale and female PpargΔ/Δmice revealed a severe in-
crease in plasma glucose, triglycerides (TGs) and free fatty acids
(NEFAs) (Fig. 2A–C), an impaired glucose tolerance (Fig. 2D), and insu-
lin resistance as suggested by the poor hypoglycemic response during
an Insulin tolerance test (ITT) (Fig. 2E). Insulin actionwas also impaired
in muscle, as demonstrated by the reduced phosphorylation of AKT
upon insulin injection (Suppl. Fig. 3). Accordingly, fed PpargΔ/Δ mice
were highly hyperinsulinemic (Fig. 2F) with plasma insulin values 16-
fold over control values. This hyperinsulinemia was accompanied by a
massive enlargement of pancreatic islets (Fig. 2G) with a 6.4 fold in-
crease in β-cell mass in PpargΔ/Δ mice (Fig. 2H). These data suggest
that β-cells are not exhausted by the very high chronic hyperglycemia.
3.3. Hyperphagia, hypermetabolism, and metabolic inﬂexibility in PpargΔ/Δ
mice
In order to get more insight into the metabolic phenotype of PpargΔ/Δ
miceweperformed indirect calorimetry experiments. PpargΔ/Δmicewere
hypermetabolic with higher oxygen consumption (Fig. 3A) and conse-
quently heat production (Fig. 3B), corresponding to a calculated 76%
higher daily metabolic rate. PpargΔ/Δ hypermetabolism was only
partially accounted for by the higher lean, metabolically active mass
(Fig. 3D). This hypermetabolismwas accompanied by a remarkable hy-
perphagia (Fig. 3E). Interestingly, the circadian oscillations of heat pro-
duction, food intake, and spontaneous locomotor activity (Fig. 3C, E, F)
were qualitatively maintained, demonstrating a preserved daily rhyth-
micity, although the amplitude was dampened (night:day activity
ratio was 2:1 in PpargΔ/Δmice as compared to 3,5:1 in controls; Fig. 3F).
The preferential use of substrates as energy source was assessed by
calculating the respiratory exchange ratio (RER = VCO2/VO2). As ex-
pected, control mice presented typical circadian oscillations of the RER
(Fig. 3G), while such rhythmicity was absent in PpargΔ/Δ mice. Males
and females exhibited a similar phenotype. Thus, PpargΔ/Δ mice are
not capable of switching between energy sources depending on the nu-
tritional status, i.e. they are metabolically inﬂexible.
Collectively, these experiments underlined three major metabolic
traits in PpargΔ/Δmice: hypermetabolism, hyperphagia, and metabolic
inﬂexibility.
3.4. Hypermetabolism is not due to an alteration of thermoregulation in
PpargΔ/Δmice
The fact that the lean,metabolically activemass did not fully account
for the hypermetabolism of PpargΔ/Δmice (see Fig. 3D) suggested that
other parameters might contribute to its onset. Notably, beside their
metabolic phenotype, PpargΔ/Δ present skin alterations, characterized
by dryness, lack of the subcutaneous fat layer, short hair and progressive
alopecia [24], which could have an effect on insulation ability. Thus,
should thermoregulation be altered in PpargΔ/Δmice due to insulation
impairment, the difference ofmetabolic rate between PpargΔ/Δ and con-
trolmicewould be expected to disappear in absence of cold stress, i.e. at
thermoneutrality. To test this hypothesis, we successively exposed the
mice to various ambient temperatures including room temperature
(23 °C) and thermoneutrality (30 °C, 32 °C, and 33 °C). In both control
and PpargΔ/Δ mice, the metabolic rate decreased from 23 °C to 32 °C,
but remained higher in PpargΔ/Δ mice than in control mice (Fig. 3H).
These data suggest that insulation does not play a signiﬁcant role in
the hypermetabolism in PpargΔ/Δ mice. Interestingly, in both control
and PpargΔ/Δmice, a further increase of the ambient temperature from
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Fig. 1. Lipoatrophy and hepatomegaly in PpargΔ/Δ mice. (A–B) Dorsal view after removal of the skin and (C) frontal view during dissection of 10 weeks old PpargΔ/Δmice and control
littermates. Note the lack of visible (A) interscapular BAT and WAT, (B) perirenal WAT and (C) mesenteric and perigonadal WAT indicated by black arrows in PpargΔ/Δ animal.
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11F. Gilardi et al. / Metabolism Clinical and Experimental 95 (2019) 8–2032 ° to 33° did not result in further drop, but rather increased the met-
abolic rate. This suggests that in both genotypes 33 °C is beyond the
upper limit of the thermoneutral zone, a temperature zonewhere active
cooling is required to prevent hyperthermia with a paradoxical in-
creases of the metabolic rate. Consistent with this notion, rectaltemperature in PpargΔ/Δmice was slightly low at 23 °C, was normal at
30 °C but was higher at 32 and 33 °C (Fig. 3I). Control mice on the
other hand maintained a constant temperature up to 33 °C. Overall,
these results indicate that the hypermetabolism in PpargΔ/Δ mice is
not due to an impairement in insulation.
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To further explore the metabolic phenotype related to energy ho-
meostasis and metabolic ﬂexibility, we submitted PpargΔ/Δ mice to
overnight (14 h) fasting.
PpargΔ/Δ mice lost more body weight than controls (Fig. 4A). Al-
though the fat loss was comparable among groups (2 g), fasting led to
an almost complete depletion of fat mass in PpargΔ/Δmice. In addition,the loss of lean mass in PpargΔ/Δ mice was twice that in control mice
(Fig. 4B–C).
Fasting resulted in a two-third decrease of glycemia and a striking
normalization of hyperinsulinemia in PpargΔ/Δmice (Fig. 4D, E). As ex-
pected, blood concentration of both ketone bodies (β-Hydroxybutyric
acid (HBA)) and the ketogenic substrates NEFAs was increased upon
fasting in control mice. In contrast, in PpargΔ/Δmice, NEFA and TG levels
were high in the fed state but decreased upon fasting and the fasting-
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suggesting that PpargΔ/Δmice are unable to normally adjust itsmetabo-
lism during fasting.3.6. Metabolic inﬂexibility and fasting-induced torpor in PpargΔ/Δ mice
To further analyse this phenotype we assessed the metabolic re-
sponse to a fed, overnight fasted, refed scheme by indirect calorimetry.In control mice, the RER rapidly dropped close to 0.7 during fasting
(shift to lipid metabolism) and reciprocally rebounded close to 1.0 dur-
ing refeeding (metabolic switch back to carbohydrates). In PpargΔ/Δ
mice, in contrast, the RER remained constant in the 0.8–0.9 range,
until 9 h into the fasting (Fig. 5A). Strikingly, during the second part of
the nocturnal fast, the VO2 and heat production had dramatically
dropped about 5-fold (Fig. 5B, C) and locomotor activitywas suppressed
(Fig. 5D), a state characteristic of fasting-induced torpor, a transient and
spontaneously reversible hibernation-like, hypometabolic state. Upon
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bolic state (Fig. 5A–C).
These results further support the notion that PpargΔ/Δ mice are se-
verely metabolically inﬂexible and intolerant to fasting.
3.7. Urinary energy loss and energy balance in PpargΔ/Δ mice
Given our previous report of impaired renal function in PpargΔ/Δmice
[29], we hypothesized that energy loss in urinemay also contribute to en-
ergy store depletion and fasting-induced torpor in PpargΔ/Δmice.
To estimate energy loss in the feces and urine, we collected them
during 24 h in the ad libitum fed state, followed by a second collection
during 5 h fasting, and ﬁnally a third collection corresponding to the
last 9 h of a 14 h fast. This protocol allowed distinguishing the earlymet-
abolic responses to fasting, when themetabolic rate was still in the nor-
mal range, from the late response, during fasting-induced torpor.
PpargΔ/Δmice are severely polyuric (Fig. 6A), consistentwith the hyper-
glycemic and thediabetic state. Thewater loss is compensatedbyan impor-
tant polydipsy (Fig. 6B). We evaluated the energy lost in urine by
measuring the concentration of main metabolites in urine. In the fed
state, PpargΔ/Δmice lose a very signiﬁcant amount of glucose (2.6 g/24 h),
but also TGs, NEFAs, ketone bodies (HBA) and proteins (Fig. 6C–G, 24 h
fed). In addition, urea excretion was strikingly increased 4.7-fold, suggest-
ing anelevationof aminoacidmetabolism(Fig. 6H, 24h fed).During fasting,the urinary loss progressively decreased in PpargΔ/Δmice for all substrates,
including the ketone bodies (Fig. 6C–G, 5hr and 9 h fasting). This latter re-
sult is in stark contrast with control mice in which HBA urinary levels in-
creased over the course of fasting (Fig. 6E), consistent with the fasting-
induced increase in plasma ketone bodies (see also Fig. 4F).
In line with the polyphagia (Fig. 6I), during the normal feeding day, we
also observed a 3-fold increase of the amount of feces produced by PpargΔ/Δ
mice (Fig. 6J), which resulted in a 3-fold higher energy loss compared to
control mice (Fig. 6K), since feces density was not altered (Fig. 6L).
By recapitulating the various energy losses, one can calculate the
portion of food energy available for bodymetabolism, i.e. themetaboliz-
able energy (Fig. 6M). The energy loss in the feces produced by PpargΔ/Δ
mice accounted for ca. 25% of energy intake, similar to controls. In fact,
the observed lower proportion of metabolizable energy in PpargΔ/Δ
mice (45% vs 75% in controls; Fig. 6M)was rather due to the very signif-
icant (30%) energy loss in urine, which thus likely contributes to induc-
ing hyperphagia in PpargΔ/Δmice.
Finally, taking into account the higher energy intake due to hyper-
phagia, the daily metabolizable energy was 79% higher in PpargΔ/Δ
mice compared to controls (15.2 vs 8.4 kcal/day), in direct proportion
to their 76% higher daily metabolic requirements (Fig. 3B).
Overall these data indicate that hyperphagia aswell as intolerance to
fasting in PpargΔ/Δmice result from excess energy requirements related
to both urinary energy loss and hypermetabolism.
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To get further insight into the impaired response to fasting, we ana-
lyzed the gene expressionof key regulators in the threemain pathways ac-
tivated in the liver upon fasting, i.e. glycogenolysis, gluconeogenesis, and
lipid oxidation. In the fed state,mRNA levels of Pdk4, a key regulator of glu-
coneogenesis, were normal in PpargΔ/Δmice. However, whereas Pdk4 ex-
pression was strongly increased only after an overnight fast in controls, it
was increased to similar levels already after a 5h fast in PpargΔ/Δmice, con-
sistent with an earlier requirement for gluconeogenesis in PpargΔ/Δmice(Fig. 7A). Along the same line, Pgc1a, another important regulator of glu-
coneogenesis which induces the expression of Pck1, was remarkably el-
evated to overnight fasted levels already in the fed and 6 h fasted states
(Fig. 7B, C). Overall, these results are consistent with both the early
fasting stress and the diabetic state of PpargΔ/Δmice.
PPARα, a key regulator of numerous genes involved in fatty acid ox-
idation upon activation by fasting, was expressed at similar levels in fed
control and PpargΔ/Δ mice and increased similarly after 5 h of fasting.
After an overnight fast, however, PPARα expression was strikingly sup-
pressed (Fig. 7D), along with the peroxisomal β-oxidation gene Acetyl-
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Hmgcs2 (Fig. 7E–F), whereas no changeswere found for the hepatic car-
nitine palmitoyltransferase (Cpt1a; Fig. 7G). Collectively, these data are
in linewith the accelerated catabolic state and early substrate depletion
during fasting in PpargΔ/Δmice.
Given the substantial loss of lean mass upon fasting and the high
urea excretion in PpargΔ/Δ mice, we also explored the metabolism of
aminoacids. As an index of aminoacid metabolism, we analyzed the ex-
pression of genes of the urea cycle, which detoxiﬁes the ammonia pro-
duced by aminoacid degradation. Strikingly, four out of ﬁve genes
involved in the urea cycle are signiﬁcantly increased in PpargΔ/Δ mice
(Got1, Asl, Ass1, Cps1, but not Oct1; Fig. 7H–L), both in the fed and inFED 5h FAST O/N FAST
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0.05, **P b 0.01, ***P b 0.0001 PpargΔ/Δ vs. control littermates.the fasting states, suggesting that facing the metabolic inﬂexibility,
PpargΔ/Δ mice developed an adaptive glutamine utilization. Thus, the
spectacular increase in lean mass in PpargΔ/Δ mice may be part of an
adaptive mechanism to ensure energy homeostasis.
4. Discussion
In the present report, we provide a thorough exploration of themet-
abolic status of mice totally deprived of adipose tissue, through consti-
tutive systemic deletion of Pparg.
Consistent with the key role of PPARγ in adipose tissue formation,
PpargΔ/Δ mice are totally lipodystrophic, with no structured orC 
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18 F. Gilardi et al. / Metabolism Clinical and Experimental 95 (2019) 8–20unstructured fat depots, except in the liver where steatosis is present. In
contrast, these mice display an important increase in leanmass, accom-
panied by organomegalia. As a consequence of the lipoatrophy, PpargΔ/Δ
develop severe type-2 diabetes, characterized by hyperglycemia,
hyperinsulinemia, polyphagia, polydispsia and polyuria. In depthmeta-
bolic analyses reveal four major ﬁndings: ﬁrst, a remarkable metabolic
inﬂexibility in both ad libitum fed state and fed/fasted/refed transitions,
with severe intolerance to fasting; second, a massive urinary loss of en-
ergy in formof glucose, lipids and proteins; third, a hypermetabolic phe-
notype related to the increase in leanmass but not to insulation defects,
which, together with urinary energy loss, contributes to the major hy-
perphagia of PpargΔ/Δmice; fourth, an activation of the urea cycle, sug-
gesting an adaptive mechanism to ensure energy homeostasis in
absence of adipose tissue.
The exploration of the effects of systemic ablation of PPARγ is an im-
portant step towards understanding how distinct PPARγ activities are
integrated in the whole organism, which might be relevant in a clinical
perspective considering that PPARγ agonists (TZDs)were the treatment
of choice for type-2 diabetes before their use was restricted due to seri-
ous side effects. Here we provide the ﬁrst study of the effects of a full,
systemic ablation of PPARγ. Interestingly, themetabolic phenotype car-
ried by Pparg+/− and PpargΔ/Δmice is quite different, with Pparg+/−
being protected against insulin-resistance, rather than being more
prone to develop this metabolic disorder, as it is seen in PpargΔ/Δ
[30,31]. The lack of the Pparg gene dosage effect on the metabolic phe-
notype is likely due to the total absence of adipose tissue in PpargΔ/Δ
compared to a diminished propensity to increase upon high fat diet in
Pparg+/−. The total lack of adipose tissue in the former is bringing its
load of metabolic consequences, which make PpargΔ/Δ mice a more
powerful model to understand fundamental aspects of energy homeo-
stasis in lipoatrophy rather than to disentangle cell-autonomous effects
of PPARγ.
To the best of our knowledge, PpargΔ/Δ mice are the ﬁrst available
model fully deprived of WAT and BAT throughout life. A-ZIP/F-1 mice,
one of the ﬁrst models resembling the Berardinelli-Seip syndrome of
generalized lypodystrophy, had aWAT reduction of almost 99% but pre-
sented a normal BAT at birth that shrank with age [32]. Mice lacking
seipin (Bscl2), the gene whose mutation is one of the causes of the
Berardinelli-Seip syndrome, have residual fat pads in visceral and sub-
cutaneous locations, before the age of 6 months [33–35]. Recently, an-
other model of severe lipoatrophy was obtained through Adipoq-Cre
mediated PPARγ deletion (PPARγFKO). However, while 8 days old
PPARγFKO mice had virtually no BAT, some inguinal and interscapular
mature adipocytes were still detectable [17]. Therefore, PpargΔ/Δ mice
represent a unique model to study the systemic and local effects of
total lack of fat tissue [24].
Several observations done in PpargΔ/Δ mice also illustrate some
limitations of the interpretation of results obtained via tissue- or cell-
speciﬁc PPARγ gene deletion. As an example, PPARγ mutant mice
presented hepatomegaly and steatosis, which, at ﬁrst sight, could
seem unexpected, especially considering that PPARγ is commonly up-
regulated in the steatotic liver. Furthermore, speciﬁc liver PPARγ dele-
tion was shown to ameliorate hepatosteatosis in both A-ZIP/F-1 and
diet-induced obese mice [36,37], while TZD treatment reduced plasma
glucose and triglycerides in liver-speciﬁc and muscle-speciﬁc PPARγ-
deleted mice [36]. However, the phenotype observed in PpargΔ/Δmice
demonstrates that, in the context of full deprivation of fat, PPARγ is
not required for lipid droplet formation in hepatocytes.
A second interesting aspect of PpargΔ/Δmice was enhanced beta cell
mass and insulin production in face of hyperglycemia. However the rel-
ative contribution of PPARγ deletion in the context of the diabetic com-
pensation remains unclear. Rosen et al. showed that loss of PPARγ in
pancreatic β-cells was associated with a hyperplastic response, but no
metabolic abnormalities [38]. More recently, a FoxO1/PPARγmediated
network was proposed as a core element for β-cell compensation and
failure in response to metabolic stress [39]. Overall our study showsthat lack of PPARγ does not lead to defects in pancreatic beta cell
function.
Lipodystrophic PpargΔ/Δ mice showed a spectacular increase in the
lean mass. This phenotype is likely related to lipodystrophy rather
than to PPARγ deletion, as it was also reported in A-ZIP/F-1 mice [32].
The causal relationship between lipodystrophy and increased lean
mass is however unknown.
Upon fasting aminoacids, mainly coming from catabolic wasting of
lean mass, are used for gluconeogenesis. In PpargΔ/Δmice, the expres-
sion of genes of the urea cycle was considerably increased in both ad
libitum fed and fasted states. Accordingly, PpargΔ/Δ mice display a rise
in the 24 h urea excretion in the fed state. This suggests an increase in
aminoacid metabolism, likely related to hyperphagia-associated higher
protein intake and possibly also to a higher mobilization of endogenous
proteins for metabolism in the post-absorptive state. During fasting,
however, there was no more elevation of urea excretion, despite the
higher expression of urea cycle genes, possibly due to an exhaustion
of the substrates easily available. In this context, the fact that PpargΔ/Δ
mice lose twice as much lean mass as controls during fasting may be
due in part to the higher urinary protein loss. Overall it is tempting to
speculate that the increased lean mass in PpargΔ/Δmice is a metabolic
adaptation to lipodystrophy and its complications.
PpargΔ/Δmice display an intriguing hypermetabolism that seems
to be mainly but not entirely explained by the increase in lean,
metabolically active mass. At ﬁrst sight, this might suggest that
other (e.g. cell-autonomous) mechanisms might account for part of
the hypermetabolism. However, it may more likely reﬂect a limita-
tion of normalization to lean mass – which relies on the assumption
that the mass-speciﬁc metabolic rate remains constant when lean
mass changes. Indeed, this assumption is not true in PpargΔ/Δ mice
that show a disproportionately high enlargement of the liver com-
pared to the total increase in leanmass. Moreover, liver has, together
with the muscle, the highest mass-speciﬁc metabolic rate [40] and is
the organ which correlates best to basal metabolic rate [41]. Thus the
hypermetabolism in PpargΔ/Δ mice is in many respects unlike other
hypermetabolic clinical situations such as HIV-associated
lipodystrophy [42], burn injury or cancer, which are associated
with sarcopenia or cachexia, particularly in chronic situations.
Metabolic inﬂexibility in PpargΔ/Δmice - as operationally deﬁned by
decreased variations in the respiratory quotient during nutritional
changes, independently of the underlying mechanisms - is suggested
by the disappearance of physiological oscillations of RER in the ad
libitum state, as well as by the absence of RER drop to 0.7 during transi-
tions from ad libitum to fasted and rebound. Although the urinary loss of
glucose (and to a lesser extent of ketone bodies) in PpargΔ/Δmice may
artiﬁcially lower the RER in the fed state, thereby ﬂattening its circadian
pattern, this would not explain why upon fasting the RER does not rap-
idly drop down to expected fasted values. The lack of organized fat tis-
sue under hormonal control of lipolysis by insulin and catecholamines
is one possible explanation for this metabolic inﬂexibility, unlike in
type 2 diabetic patients where metabolic inﬂexibility rather reﬂects an
impaired insulin axis [43–45].
Upon fasting, PpargΔ/Δmice rapidly deplete their body energy stores
and enter torpor, a hypometabolic, hibernation-like state. Although
lipodystrophy per se plays a major role, it is interesting to note that lep-
tin deﬁciency has been described as a possible actor for the entry in
torpor-like state upon fasting, as observed in both obese ob/ob mice
and lipodystrophic A-ZIP/F-1 mice [46].
Several intriguing questions remain, such as how is feeding regu-
lated in PpargΔ/Δmice in absence of leptin, and to what extent is the ab-
sence of leptin relevant to the increase in body weight and lean mass
compared to controls beyond 8 weeks of age.
More generally, this discussion highlights the complexity of themet-
abolic interplay between lack of adipose tissue, increased leanmass, hy-
permetabolism, hyperphagia and metabolic inﬂexibility. A molecular
and system approach to understand the possible mechanisms of
19F. Gilardi et al. / Metabolism Clinical and Experimental 95 (2019) 8–20adaptationwould provide some clues on fundamental aspects of energy
metabolism, as well as on related questions of clinical relevance.
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